Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Myeloproliferative Disorders 1Leukemia, Myeloid, Accelerated Phase 1

Interventions

Cyclophosphamide 47fludarabine phosphate 43Peripheral Blood Stem Cell Transplantation 40Busulfan 37Tacrolimus 34Methotrexate 30Antilymphocyte Serum 28Mycophenolic Acid 22Whole-Body Irradiation 21Radiotherapy 21Cyclosporine 21Methylprednisolone 17Melphalan 15Filgrastim 15Cytarabine 13Cord Blood Stem Cell Transplantation 13merphos 11Etoposide 10sargramostim 8Rituximab 8Thiotepa 7Sirolimus 6thymoglobulin 5Transplantation 5Interferon-alpha 5ponatinib 4Imatinib Mesylate 4Granulocyte Colony-Stimulating Factor 4CT-P10 4fludarabine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Myeloid, Accelerated Phase × olverembatinib × Clear all
NCT03883100 2023-04-03

A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation

Ascentage Pharma Group Inc.

Phase 2 Unknown
23 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Accelerated Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡